Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its ...

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Biogen Inc. BIIB shares rallied 7% in the last trading session to close at $216.03. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, ...

Woods noted that Biogen has multiple focuses across autoimmune kidney diseases and Alzheimer's, unlike many names in the ...

In August, the U.S. Food and Drug Administration (FDA) stated that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but ...

Shares of Biogen Inc. BIIB rose 3.04% to $216.12 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX remaining mostly unchanged at 7,483 ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company’s market value has increased by approximately $3.3 billion over ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...